arrow
K

Kenneth S. Thress

AstraZeneca
H指数:28
被引数:7,912

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer

来自AURA3试验的组织和血浆中的表皮生长因子受体突变分析: 奥希替尼与铂类培美曲塞治疗T790M突变阳性的晚期非小细胞肺癌

CANCER
IF5.1
2019-11-2697
OAAI
A clinically validated comprehensive companion diagnostic platform for care of patients with advanced cancer
2018-07-011
PRE
Outcomes in patients with non-small-cell lung cancer and acquired Thr790Met mutation treated with osimertinib: a genomic study

奥希替尼治疗非小细胞肺癌伴获得性Thr790Met突变患者的结局: 一项基因组学研究

2018-02-01129
PREAI
Preclinical Comparison of Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC Brain Metastases Models, and Early Evidence of Clinical Brain Metastases Activity
2016-10-13590
OAAI
Analysis of cell-free plasma DNA (cfDNA) identifies 3 molecular subtypes of acquired resistance to AZD9291, a novel EGFR tyrosine kinase inhibitor (TKI), in patients (pts) with advanced lung cancer
2015-08-011
PRE
Acquired Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 Is Associated with Increased Dependence on RAS Signaling in Preclinical Models

对突变选择性EGFR抑制剂AZD9291的获得性耐药与临床前模型对RAS信号的依赖性增加有关

2015-06-14275
OAAI
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M

获得性EGFR C797S突变介导EGFR T790M的非小细胞肺癌对AZD9291的耐药性

2015-05-041.4K
OAAI
Investigating resistance to AZD9291
2014-10-010
PRE